Despite a return to revenue growth in 2023’s second quarter, troubled Mallinckrodt continues to weigh its financial options, according to CEO Siggi Olafsson. Among them is a new bankruptcy bid that could get the company off the hook for more than $1 billion in opioid settlement payments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,